首页> 外文期刊>Journal of molecular recognition: JMR >Atomic force microscopy study of the antigen-antibody binding force on patient cancer cells based on ROR1 fluorescence recognition
【24h】

Atomic force microscopy study of the antigen-antibody binding force on patient cancer cells based on ROR1 fluorescence recognition

机译:基于ROR1荧光识别的抗原抗体对患者癌细胞的结合力的原子力显微镜研究

获取原文
获取原文并翻译 | 示例
           

摘要

Knowledge of drug-target interaction is critical to our understanding of drug action and can help design better drugs. Due to the lack of adequate single-molecule techniques, the information of individual interactions between ligand-receptors is scarce until the advent of atomic force microscopy (AFM) that can be used to directly measure the individual ligand-receptor forces under near-physiological conditions by linking ligands onto the surface of the AFM tip and then obtaining force curves on cells. Most of the current AFM single-molecule force spectroscopy experiments were performed on cells grown in vitro (cell lines) that are quite different from the human cells in vivo. From the view of clinical practice, investigating the drug-target interactions directly on the patient cancer cells will bring more valuable knowledge that may potentially serve as an important parameter in personalized treatment. Here, we demonstrate the capability of AFM to measure the binding force between target (CD20) and drug (rituximab, an anti-CD20 monoclonal antibody targeted drug) directly on lymphoma patient cancer cells under the assistance of ROR1 fluorescence recognition. ROR1 is a receptor expressed on some B-cell lymphomas but not on normal cells. First, B-cell lymphoma Raji cells (a cell line) were used for ROR1 fluorescence labeling and subsequent measurement of CD20-rituximab binding force. The results showed that Raji cells expressed ROR1, and the labeling of ROR1 did not influence the measurement of CD20-rituximab binding force. Then the established experimental procedures were performed on the pathological samples prepared from the bone marrow of a follicular lymphoma patient. Cancer cells were recognized by ROR1 fluorescence. Under the guidance of fluorescence, with the use of a rituximab-conjugated tip, the cellular topography was visualized by using AFM imaging and the CD20-Rituximab binding force was measured by single-molecule force spectroscopy.
机译:药物-靶标相互作用的知识对于我们对药物作用的理解至关重要,并且可以帮助设计更好的药物。由于缺乏适当的单分子技术,在原子力显微镜(AFM)出现之前,配体-受体之间相互作用的信息很少,可用于直接在接近生理条件下测量各个配体-受体力通过将配体连接到AFM尖端的表面上,然后获得细胞上的力曲线。当前大多数AFM单分子力光谱实验是在体外生长的细胞(细胞系)上进行的,该细胞与体内人细胞有很大不同。从临床实践的角度来看,直接在患者癌细胞上研究药物-靶标相互作用将带来更多有价值的知识,这些知识可能潜在地成为个性化治疗中的重要参数。在这里,我们展示了AFM在ROR1荧光识别的帮助下直接测量淋巴瘤患者癌细胞上靶标(CD20)与药物(利妥昔单抗,一种抗CD20单克隆抗体靶向药物)之间的结合力的能力。 ROR1是在某些B细胞淋巴瘤上表达但在正常细胞上不表达的受体。首先,将B细胞淋巴瘤Raji细胞(一种细胞系)用于ROR1荧光标记并随后测量CD20-利妥昔单抗的结合力。结果显示,Raji细胞表达ROR1,并且ROR1的标记不影响CD20-利妥昔单抗结合力的测量。然后对从滤泡性淋巴瘤患者的骨髓制备的病理样品进行既定的实验程序。癌细胞被ROR1荧光识别。在荧光的指导下,使用缀有利妥昔单抗的针尖,通过AFM成像观察细胞形态,并通过单分子力谱法测量CD20-利妥昔单抗结合力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号